ISSN: 2148-4902 | E-ISSN: 2536-4553
Northern Clinics of Istanbul A single center’s experience of the extra-pulmonary neuroendocrine carcinomas [North Clin Istanb]
North Clin Istanb. Ahead of Print: NCI-47887 | DOI: 10.14744/nci.2021.47887

A single center’s experience of the extra-pulmonary neuroendocrine carcinomas

Emir Celik, Nilay Sengul Samanci, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas, Gulin Alkan, Abdulhalim Senyigit, Hande Turna
Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Medical Oncology, Turkey

Introduction: Extra-pulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.

Methods: This retrospective study was conducted based on medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.

Results: 47 patients were included in the study. 72.3% (n = 34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide was 5.83 months (95% CI 4.46-7.20), whereas the median overall survival (OS) of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01-18.18). There was no difference in PFS and OS between patients with and without liver metastasis.

Conclusion: The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.

Keywords: Extra-pulmonary neuroendocrine carcinoma, platinum and etoposide, liver metastasis

Akciğer dışı nöroendokrin karsinomlar: Tek merkez deneyimi

Emir Celik, Nilay Sengul Samanci, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas, Gulin Alkan, Abdulhalim Senyigit, Hande Turna
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İstanbul

Giriş: Ekstra-pulmoner nöroendokrin karsinomlar (EP-NEK) nadir görülen tümörlerdir ve standart tedavileri netleşmemiştir. Bu çalışmada amaç platin-etoposid kombinasyonunun sağ kalım ve tedavi etkinliğini araştırmaktır.

Yöntem: Bu retrospektif çalışma, Ocak 2010-Mart 2020 yılları arasındaki tıbbi kayıtlar ile yapıldı. Patolojik olarak EP-NEK tanısı olan hastalar dahil edildi.

Bulgular: Çalışmaya 47 hasta dahil edildi. Hastaların %72.3’ü (n=34) ilk tanıda metastatikti. En sık primer tümör yerleşim yeri mideydi. Platin/etoposid alan hastalarda ortanca progresyonsuz sağ kalım (PSK) 5.83 ay idi (95% CI 4.46-7.20). İlk tanıda metastatik olan hastalarda ortanca genel sağ kalım (GSK) ise 13.6 ay idi (95% CI 9.01-18.18). Karaciğer metastazı olan ve olmayan gruplar arasında PSK ve GSK farkı yoktu.

Sonuç: EP-NEK tanılı hastalarda platin/etoposid tedavi sonuçları yüz güldürücü değildir. Yeni ve daha efektif tedavilere ihtiyaç olduğu aşikardır. (NCI-2020-0334.R1)

Anahtar Kelimeler: Ekstra-pulmoner nöroendokrin karsinom, platin ve etoposid, karaciğer metastazı



Corresponding Author: Emir Celik
Manuscript Language: English
LookUs & Online Makale